InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.755 0.02 (2.72%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$360 Notification of AGM date 2 Oct 2018 4:40PM $1.560 $0.755 fallen by 51.60%
$360 Change in substantial holding 14 Sep 2018 8:18AM $1.460 $0.755 fallen by 48.29%
$360 DEP irinotecan outperforms in pancreatic cancer model 5 Sep 2018 10:16AM $1.260 $0.755 fallen by 40.08%
$360 AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy 31 Aug 2018 10:00AM $1.150 $0.755 fallen by 34.35%
$360 Appendix 4G - Corporate Governance Statement 21 Aug 2018 1:32PM $1.145 $0.755 fallen by 34.06%
$360 Annual report and full year financial results 21 Aug 2018 1:28PM $1.150 $0.755 fallen by 34.35%
$360 Quarterly Cashflow Report 17 Jul 2018 10:17AM $1.145 $0.755 fallen by 34.06%
$360 VivaGel BV NDA advances to next stage of FDA review 9 Jul 2018 2:04PM $1.115 $0.755 fallen by 32.29%
$360 Starpharma licenses VivaGel BV to Mundipharma for Europe 27 Jun 2018 8:49AM $1.100 $0.755 fallen by 31.36%
$360 Change in substantial holding 6 Jun 2018 8:20AM $1.175 $0.755 fallen by 35.74%
$360 Change in Director's Interest Notice - R Thomas 17 May 2018 4:19PM $1.255 $0.755 fallen by 39.84%
$360 Mundipharma licenses Starpharma's VivaGel BV 3 May 2018 9:53AM $1.185 $0.755 fallen by 36.29%
$360 Appendix 4C - Quarterly Cashflow Report 30 Apr 2018 12:18PM $1.190 $0.755 fallen by 36.55%
$360 Starpharma completes US New Drug Application for VivaGel BV 30 Apr 2018 10:34AM $1.163 $0.755 fallen by 35.05%
$360 Starpharma to present at OTCQX Virtual Investor Conference 11 Apr 2018 2:29PM $1.210 $0.755 fallen by 37.60%
$360 Change in Director's Interest Notice - J Fairley 21 Mar 2018 11:59AM $1.180 $0.755 fallen by 36.02%
$360 Change in Director's Interest Notice - R Thomas 20 Mar 2018 10:47AM $1.135 $0.755 fallen by 33.48%
$360 Appendix 3B 20 Mar 2018 10:46AM $1.135 $0.755 fallen by 33.48%
$360 Change in Director's Interest Notice - R Thomas 15 Mar 2018 9:54AM $1.270 $0.755 fallen by 40.55%
$360 Change in Director's Interest Notice - P Turvey 12 Mar 2018 8:54AM $1.355 $0.755 fallen by 44.28%
$360 Change in Director's Interest Notice - J Fairley 12 Mar 2018 8:52AM $1.355 $0.755 fallen by 44.28%
$360 Change in Director's Interest Notice - R Thomas 5 Mar 2018 11:52AM $1.425 $0.755 fallen by 47.02%
$360 Interim Report and Half-Yearly Financial Results 26 Feb 2018 9:29AM $1.435 $0.755 fallen by 47.39%
$360 Starpharma receives $3.7M R&D tax incentive refund 22 Feb 2018 9:28AM $1.375 $0.755 fallen by 45.09%
$360 Shareholder Update February 2018 19 Feb 2018 10:34AM $1.385 $0.755 fallen by 45.49%

501 - 525 of 884 results

Page 21 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.